Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Ads After Higher Wegovy Dose Approval
Updated
Updated · NBC News · Jul 21
Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Ads After Higher Wegovy Dose Approval
3 articles · Updated · NBC News · Jul 21
Summary
US federal court filings show Novo Nordisk sued Eli Lilly, alleging ads for Zepbound and Mounjaro mislead consumers in the fast-growing obesity-drug market.
Novo says Lilly’s campaigns use outdated weight-loss comparisons against lower Wegovy doses, not the higher dose Novo later won approval to sell.
Lilly’s Zepbound had beaten Wegovy in a head-to-head trial last year, but Novo argues that result no longer reflects the product now on the market.
The lawsuit adds a legal front to intensifying competition between the two drugmakers as they battle for leadership in blockbuster weight-loss and diabetes treatments.